The gene TLR3 (toll like receptors) is mapped to human chromosome 4q35.1. Tlrs are predominantly expressed in antigen-presenting cells (APCs) such as macrophages and dendritic cells.
The protein encoded by this gene is a member of the Toll-like receptor (TLR) family which plays a fundamental role in pathogen recognition and activation of innate immunity. TLRs are highly conserved from Drosophila to humans and share structural and functional similarities. They recognize pathogen-associated molecular patterns (PAMPs) that are expressed on infectious agents, and mediate the production of cytokines necessary for the development of effective immunity. The various TLRs exhibit different patterns of expression. This receptor is most abundantly expressed in placenta and pancreas, and is restricted to the dendritic subpopulation of the leukocytes. It recognizes dsRNA associated with viral infection, and induces the activation of NF-kappaB and the production of type I interferons. It may thus play a role in host defense against viruses. Use of alternative polyadenylation sites to generate different length transcripts has been noted for this gene.
Immunogen
TLR3 (Q99MB1, 28-63) This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the N-terminal region of mouse TLR3.
Biochem/physiol Actions
Toll-like receptors (TLRs) are essential element of nonspecific innate inflammatory response. Tlr3 is a pathogen recognition receptor that recognizes dsRNA of viruses and induces an innate immune response against the pathogen. It recognizes damage-associated and pattern-associated molecular pattern molecules. TLRs induce immune tolerance by activating transcription factors and the expression of downstream genes. TLRs maintain immune homeostasis by identification and rejection of self-senescent and pathological cells. Tlr3 is expressed in high levels on several cancer type cells and serves as an immunotherapeutic target to initiate both innate and adaptive immune responses. Tlr3 possesses anti-tumoral potential by inducing a strong type I interferon response. Tlr3 is known to induce strong CD8+ T cell (cytotoxic T lymphocytes) responses by promoting cross-priming of endogenous antigens. TLR3 is known to mediate hippocampal memory. Due to its wide expression in the mesolimbic dopamine system, TLR3 signaling might control alcohol consumption.
Physical form
Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Toll-like receptors (TLRs) are innate immunity-related receptors. Many studies have indicated the involvement of TLRs in neurophysiology and neuropathology. One study showed that TLR3 regulates hippocampal memory and is highly expressed in the mesolimbic dopamine system, suggesting that TLR3 signaling
International journal of molecular sciences, 17(12), 1-11 (2016-12-06)
Autoimmune regulator (Aire) mutations result in autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED), which manifests as multi-organ autoimmunity and chronic mucocutaneous candidiasis (CMC). Indendritic cells (DCs), pattern recognition receptors (PRR), such as Toll-like receptors (TLRs), are closely involved in the recognition
Epilepsy affects 60 million people worldwide. Despite the development of antiepileptic drugs, up to 35% of patients are drug refractory with uncontrollable seizures. Toll-like receptors (TLRs) are central components of the nonspecific innate inflammatory response. Because TLR3 was recently implicated
Evidence that a deficient innate immune response toward the bacterial flora of the gut plays a role in the pathogenesis of inflammatory bowel disease (IBD) is growing. This is underscored by the finding of the association between CARD15 variants and
Targeting TLR3 through formulations of polyI:C is widely studied as an adjuvant in cancer immunotherapy. The efficacy of such targeting has been shown to increase in combination with anti-PD-L1 treatment. Nevertheless, the mechanistic details of the effect of polyI:C on
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.